533 related articles for article (PubMed ID: 30888232)
1. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Uckun FM; Qazi S
Expert Opin Ther Pat; 2010 Nov; 20(11):1457-70. PubMed ID: 20831363
[TBL] [Abstract][Full Text] [Related]
4. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
6. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
7. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
8. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
9. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
11. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
[TBL] [Abstract][Full Text] [Related]
12. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
13. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
14. Orelabrutinib: First Approval.
Dhillon S
Drugs; 2021 Mar; 81(4):503-507. PubMed ID: 33704654
[TBL] [Abstract][Full Text] [Related]
15. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
16. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
[TBL] [Abstract][Full Text] [Related]
17. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
Brullo C; Villa C; Tasso B; Russo E; Spallarossa A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299259
[TBL] [Abstract][Full Text] [Related]
18. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
19. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
20. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
